Details for Patent: 9,114,068

Which drugs does patent 9,114,068 protect, and when does it expire?

Patent 9,114,068 protects CALDOLOR and is included in one NDA.

This patent has twenty-three patent family members in nine countries.

Summary for Patent: 9,114,068

Scope and claims summary:

Title:	Treating patients with intravenous ibuprofen
Abstract:	Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.
Inventor(s):	Pavliv; Leo (Cary, NC), Rock; Amy Dix (Thompson Station, TN)
Assignee:	Cumberland Pharmaceuticals, Inc. (Nashville, TN)
Application Number:	14/264,267
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 9,114,068

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-002	Jun 11, 2009		RX	Yes	Yes	9,114,068					METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL

International Family Members for US Patent 9,114,068

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009350474
Australia	2010274030
Brazil	112012000773